Trial reportBlood advances2026
Impact of oral iron dosing regimens on iron biomarkers during pregnancy: insights from the PANDA trial.
Trial report in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
abstractIron deficiency during pregnancy remains a global health burden, yet pregnancy-related physiological adaptations complicate the interpretation of iron biomarkers. Modified oral iron regimens are increasingly used to balance iron intake, absorption, and tolerability. This study evaluated the effects of daily, alternate-day, and 3-times-weekly oral iron supplementation on iron status biomarkers in nonanaemic pregnant participants. In the PANDA (Primary prevention of maternal Anemia to avoid preterm Delivery and other Adverse outcomes) dose-finding trial, nonanemic pregnant women were randomized to receive 200 mg of ferrous sulfate daily, on alternate days, or 3-times-weekly. Blood samples were collected at 9 to 13 and 26 to 30 weeks' gestation (N = 135 participants). Hepcidin and soluble transferrin receptor (sTfR) were measured by enzyme-linked immunosorbent assay, and serum iron, ferritin, transferrin, and C-reactive protein using automated biochemistry. Linear mixed-effects models assessed within- and between-group biomarker changes. Hepcidin, ferritin, and transferrin saturation declined significantly between baseline and follow-up in all groups (P< .001). sTfR increased in the alternate-day (P = .003) and 3-times-weekly groups (P< .001), but not in the daily group (P = .084). Despite supplementation and maintenance of hemoglobin levels, 69% to 72% of women were iron deficient (ferritin <30 μg/L) at 26 to 30 weeks' gestation. Iron status declined across pregnancy regardless of supplementation regimen, suggesting physiological adaptations may dominate over dosing effects. The absence of a significant rise in sTfR in the daily group suggests that daily dosing best meets the iron demand of pregnancy, though confirmation in larger, adequately powered studies is required. This trial was registered at the UK trial registry as #ISRCTN12911644.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.